Monday, October 3, 2022
HomeSports MedicineRepligen expands course of analytics portfolio with DRS Daylight Options settlement

Repligen expands course of analytics portfolio with DRS Daylight Options settlement



Repligen Company, a life sciences firm centered on bioprocessing expertise management, immediately introduced it has entered right into a strategic partnership and unique license settlement with DRS Daylight Options to increase using mid-infrared (mid-IR) expertise within the bioprocessing market.

Via this settlement, Repligen will assume duty for the commercialization of Culpeo®, in addition to the event of future merchandise and applied sciences in partnership with DRS Daylight Options (“Daylight”). Each firms will concentrate on increasing the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) primarily based options and integrating these options into Repligen Chromatography and Filtration techniques to increase the businesses’ presence within the fast-growing Course of Analytics Know-how (PAT) phase of the bioprocessing market.

Daylight’s patented QCL-IR expertise measures larger order protein and nucleic acid construction, facilitating the measurement of protein aggregation, focus and nucleic acid content material and different essential attributes in organic manufacturing processes. Correct readouts can be found in seconds, enabling real-time course of monitoring in upstream and downstream manufacturing.

San Diego-based Daylight specializes within the growth and manufacturing of modern options primarily based on its QCL expertise platform, which operates all through the mid-IR spectral vary. Daylight, identified for best-in-class merchandise supporting business, analysis, and aerospace and protection markets, entered the bioprocessing market in 2018 with its ground-breaking Culpeo® instrument.

We’re delighted to have signed this settlement with DRS Daylight Options, which enhances our current analytics portfolio from C Applied sciences, a pioneer in real-time, in-line course of monitoring options. We imagine that the Daylight portfolio will serve to speed up and increase adoption of in-line course of monitoring within the bioprocessing trade. We look ahead to working with Tim Day and the workforce at Daylight.”

Tony J. Hunt, CEO, Repligen Company

Dr. Timothy Day, Senior Vice President and Basic Supervisor, DRS Daylight Options, stated, “We’re very excited to accomplice with Repligen to make QCL-IR primarily based options a game-changing expertise in PAT. We imagine Repligen is one of the best accomplice to perform this, given their success with C Applied sciences and their monitor file of innovation in bioprocessing. We look ahead to working along with Tony Hunt and the Repligen workforce to offer bioprocessing clients this ground-breaking expertise to measure essential course of parameters in biologics manufacturing. With real-time and excessive reliability outcomes, Culpeo® will in the end enhance manufacturing yields, cut back prices and guarantee product high quality.” 

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments